Rockwell Medical, Inc. (DE) (RMTI) Stock: Buy, Sell, or Hold?
RMTI - Rockwell Medical, Inc. (DE) Common Stock
$7.99
0.00 (0.00%)
â˛
5d:
-2.26%
30d:
+11.52%
90d:
+1101.66%
WAIT
LOW Confidence
Analysis Updated: Sep 4, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When RMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RMTI is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RMTI is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: RMTI is currently trading at $7.99, which is considered slightly high relative to its 30-day fair value range of $7.22 to $8.01. From a valuation perspective, the stock is trading at a discount (Forward PE: -47.0) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RMTI is in a strong uptrend. Immediate support is located at $7.70, while resistance sits at $8.50.
Market Sentiment: RMTI scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+150.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RMTI is in a strong uptrend. Immediate support is located at $7.70, while resistance sits at $8.50.
Market Sentiment: RMTI scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+150.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.22 -
$8.01
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 150.5% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 43/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.22 -
$8.01
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.70
Resistance Level
$8.50
Current Trend
Strong Uptrend
Technical data as of
Sep 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-46.97
Wall Street Target
$20.00
(+150.5%)
Revenue Growth (YoY)
10.6%
Profit Margin
-7.3%
PE vs Historical
-47.0 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: September 07, 2026 4:29 AM ET
Data refreshes hourly during market hours. Next update: 5:29 AM
Data refreshes hourly during market hours. Next update: 5:29 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 61 BUY |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 77 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 41 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 44 HOLD |
